PETITION FOR REVIVAL OF AN APPLICATION FOR PATENT ABANDONED UNINTENTIONALLY UNDER 37 C.F.R. 1.137(b)

FEB 2	2 2005
-------	--------

First Nan	ned Inventor:	Jorn Bullerdiek et al.	Atty. Docket No.:	BETAND SP0010US		
Serial No	•	09/890,684	Group Art Unit:	N/A		
Filed:		04 February 2000	Examiner:	N/A		
Title: Preparation for the Prevention and/or Treatment of a Tissue Change of Mesenchymal Origin						

Mail Stop Petitions Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

01 FC:2453

The above-identified application became abandoned for failure to file a timely and proper reply to a notice or action by the Patent and Trademark Office mailed on September 15, 2003. The date of abandonment is the day after the expiration date of the period set for reply in the Office notice or action plus any extensions of time actually obtained.

APPLICANT HEREBY PETITIONS FOR REVIVAL OF THIS APPLICATION

	11111	TOTAL TIDICAL TENTIONS FOR REVIVAE OF THIS ALL DIOMINO.
1.	Petition X . □	on Fee: Small Entity Fee: \$750.00 - Applicant claims small entity status (See 37 CFR 1.27.) Other than Small Entity: \$1,500.00
a j an	A. paper cop d 1.825(and/or fee: The reply and/or fee to the above-noted Office action in the form of Reply to the "Notification to Comply With Requirements For Patent Applications Containing Nucleotide And/Or Amino Acid Sequence Disclosures": \[\begin{align*} \text{D} & has been filed previously on \(\text{L} & is enclosed herewith (including, a computer readable form of the Sequence Listing by of the Sequence Listing, Statement Under 37 C.F.R. Sections 1.821(e), 1.821(f), 1.825(a) and a copy of the September 15, 2003 "Notification to Comply With Requirements For blications Containing Nucleotide And/or Amino Acid Sequence Disclosures").
	B.	The Issue Fee of \$ □ has been paid previously paid on □ is enclosed herewith.
	X	Since this utility/plant application was filed on or after June 8, 1995, no terminal disclaimer is required. (Control of the control of the c
V3/ V2/ 2003	UNAHUHAG	VVVVVIVO V707V001

U.S.S.N. 09/890,684 Page 1 of 3

750.00 OP

- ☐ A terminal disclaimer and disclaimer fee (37 CFR 1.20(d) of ☐ \$55.00 for a small entity, or ☐ \$110.00 for other than small entity, disclaiming a period equivalent to the period of abandonment is enclosed herewith.
- 4. Statement. The entire delay in filing the required reply from the due date for the required reply until the filing date of a grantable petition under 37 C.F.R. 1.137(b) was unintentional.
- 5. Miscellaneous. Enclosed is a copy of the Decision on Petition mailed January 13, 2005 in connection with the above-identified application.
- 6. If any additional fees are incurred as a result of the filing of this paper, authorization is given to charge deposit account number 23-0785.

Respectfully submitted,

Lisa V Mueller Reg No 38 978

WOOD, PHILLIPS, KATZ, CLARK & MORTIMER

Citicorp Center, Suite 3800 500 West Madison Street Chicago, Illinois 60661-2511 312/876-1800

Enclosures: \underline{X} Fee payment.

X Reply

☐ Terminal Disclaimer Form.

☐ Small Entity Status Form.

X Other: Decision on Petition mailed on January 13, 2005, computer readable copy of the Sequence Listing, paper copy of the Sequence Listing, Statement Under 37 C.F.R. Sections 1.821(e), 1.825(a) and 1.825(b) and a copy of the September 15, 2003 "Notification to Comply With Requirements For Patent Applications Containing Nucleotide And/or Amino Acid Sequence Disclosures".

U.S.S.N. 09/890,684 Page 2 of 3



CERTIFICATE OF MAILING BY EXPRESS MAIL

I hereby certify that this Petition For Revival of An Application For Patent Abandoned Unintentionally Under 37 CFR 1.137(b) is being deposited with the United States Postal Service with sufficient postage at Express Mail Label No. EV 348840515 US in an envelope addressed to: Mail Stop Petitions, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on February 22, 2005.

Aidah Abdallah

ylah abdallah

U.S.S.N. 09/890,684 Page 3 of 3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

pplicant: Jorn Bullerdiek et al.) Docket No.: BOH6278P0010US

Serial No.: 09/890,684) Group Art Unit: N/A

Filed: August 3, 2001) Examiner: N/A

For: Preparation for the Prevention)

And/or Treatment of a Tissue Change of

Mesenchymal Origin

Commissioner For Patents PO Box 1450 Alexandria, VA 22313-1450

Response to Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures

In response to the Response to Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures mailed on September 15, 2003 in connection with the above-identified application, Applicants herewith enclose:

- (a) A computer readable form (CRF) of the "Sequence Listing" (corrected);
- (b) A copy of the "Sequence Listing" in paper format; and
- (c) A statement by Armin K. Bohmann that the contents of the paper and the computer readable form of the Sequence Listing are the same and do include no new matter, as required by 37 CFR Sections 1.821(e), 1.821(f), 1.821(a) and 1.825(b).

If any additional fees are incurred as a result of the filing of this paper, authorization is given to charge deposit account number 23-0785.

Respectfully submitted, Jorn Bullerdiek & al.

Rv.

Lisa V. Mueller Reg. No. 38,978

Attorney for Applicant

WOOD, PHILLIPS, KATZ, CLARK & MORTIMER 500 W. Madison Street

Suite 3800

Chicago, IL 60661 Tel.: (312) 876-2109 Fax.: (312) 876-2020



CERTIFICATE OF MAILING BY EXPRESS MAIL

I hereby certify that this Response to Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or Armino Acid Sequence Disclosures is being deposited with the United States Postal Service with sufficient postage as Express Mail Label No.: EV 348840515 US in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on February 22, 2005.

Dah Wolallach

Aidah Abdallah



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Jorn Bullerdiek et al.)		
Serial No.:	09/890,684)	Group Art Unit:	N/A
		Ś	Examiner:	N/A
Filed:	August 3, 2001)	Examiner.	14/21
For:	Preparation for the Prevention)		
And/or Treat	ment of a Tissue Change of			
Mesenchyma	ıl Origin			

Commissioner For Patents PO Box 1450 Alexandria, VA 22313-1450

STATEMENT UNDER 37 C.F.R. SECTIONS 1.821(e), 1.821(f), 1.825(a), 1.825(b)

Sir:

I, Armin K. Bohmann declare:

- 1. The enclosed sequence listing information recorded in the computer readable form is identical to the enclosed written paper form of the sequence listing and does not contain any new matter.
- 2. That I believe that all statements made herein of my own knowledge are true and that all statements made on information and belief are true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the patent application in the United States of America or any patent issuing thereon.

Date

Armin K. Bohmann

Date Mailed: 09/15/2003

The following items MUST be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

The following items MUST be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
 - The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
 - APPLICANT MUST PROVIDE:
 - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
 - For Rules Interpretation, call (703) 308-4216
 - To Purchase Patentin Software, call (703) 306-2600
 - For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice **MUST** be returned with the response.

INDIA L EVANS Telephone: (703) 305-2936 PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO INTERNATIONAL APPLICATION NO

ATTY DOCKET NO

09/890,684

PCT/DE00/00364

BOH6277P0001

FORM PCT/DO/EO/922 (371 Formalities Notice)





COMMISSIONER FOR PATENTS
JNITED STATES PATENT AND TRADEMARK OFFICE
P.O. BOX 1450
ALEXANDRIA, VA 223131450

WOOD PHILLIPS KATZ CLARK & MORTIMER

500 W. Madison Street

Suite 3800

Chicago, IL 60661

In re Application of: BULLERDIEK, Jorn

U.S. Application No.: 09/890,684

PCT No.: PCT/DE00/00364

International Filing Date: 04 February 2000

Priority Date: 04 February 1999

Attorney's Docket No.: BOH6278P0010US

For: PREPARATION FOR THE PREVENTION

AND/OR TREATMENT OF A TISSUE CHANGE OF MESENCHYMAL ORIGIN

Deceive

WOOD, PHILLIPS. ET

DECISION ON PETITION

This decision is issued in response to applicant's "Petition for Removal of a Holding of Abandonment Under 37 CFR 1.181(a)" filed 06 May 2004, and resubmitted on 09 November 2004 and 07 December 2004. No petition fee is required.

BACKGROUND

On 04 February 2000, applicant filed international application PCT/DE00/00364 which claimed a priority date of 04 February 1999 and which designated the United States. On 10 August 2000, a copy of the international application was communicated to the United States Patent And Trademark Office ("USPTO") by the International Bureau ("IB"). The deadline for payment of the basic national fee was thirty months from the priority date, i.e., 04 August 2001.

On 03 August 2001, applicant filed a transmittal letter for entry into the national stage in the United States accompanied by, among other materials, payment for the basic national fee, an English translation of the international application, and an executed declaration.

On 09 November 2001, the United States Designated/Elected Office (DO/EO/US) mailed a Notification Of Missing Requirements (Form PCT/DO/EO/905), indicating that proper sequence listing materials, including a computer readable for (CRF) of the sequence listing, were required.

On 29 January 2002, applicant filed a response to the Notification Of Missing Requirements which included a purported CRF of the sequence listing and a "Statement Under 37 CFR 1.821(f)."

On 01 April 2002, the DO/EO/US mailed a Notification Of Defective Response (Form PCT/DO/EO/916) indicating that applicant's response to the Notification Of Missing

Requirements was defective and that proper sequence listing materials were still required. The Notice was accompanied by a "CRF Problem Report" which indicated that the CRF filed by applicant in response to the Notification Of Missing Requirements was damaged. The Notice provided a one-month non-extendable response deadline.

On 22 April 2002, applicant filed a response to the Notification Of Defective Response which states that it was accompanied by a CRF of the sequence listing.

On 03 December 2002, the DO/EO/US mailed a Notification of Abandonment (Form PCT/DO/EO/909).

On 15 September 2003, the DO/EO/US mailed a "Withdrawal Of Previously Sent Notice" stating that the Notification of Abandonment mailed 03 December 2002 was issued in error and was therefore withdrawn. Also on 15 September 2003, the DO/EO/US mailed a "Notification To Comply With Requirements For Patent Applications Containing Nucleotide And/Or Amino Acid Sequence Disclosures" (Form PCT/DO/EO/922) again requiring submission of a readable CRF.

On 20 November 2003, applicant filed a response to the "Notification To Comply With Requirements For Patent Applications Containing Nucleotide And/Or Amino Acid Sequence Disclosures."

On 26 April 2004, the DO/EO/US mailed a second Notice Of Abandonment (Form PCT/DO/EO/909). This Notice indicates that the application is abandoned for failure to file a response to the Notification mailed 15 September 2003.

On 06 May 2004, applicant filed the petition to withdraw the abandonment considered herein. The petition notes that a timely response to the 15 September 2003 Notification was filed on 20 November 2003. The petition includes a copy of the previously filed response, a copy of the stamped return postcard, and a replacement copy of the CRF included with the earlier submission. On 09 November 2004 and 07 December 2004, applicant resubmitted copies of the petition materials.

DISCUSSION

The application file contains a copy of the "Response to Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures." filed by applicant. This response bears a USPTO receipt stamp dated 20 November 2003, confirming that a timely response was filed to the "Notification To Comply With Requirements For Patent Applications Containing Nucleotide And/Or Amino Acid Sequence Disclosures" mailed 15 September 2003, as asserted by applicant in the present petition. Moreover, the itemized return postcard included with the present petition confirms that

the 20 November 2003 submission included a computer disc containing a purported CRF of the sequence listing.

However, the sequence materials contained on this CRF are not in proper form, as detailed in the "Raw Sequence Listing Error Report" accompanying this decision.\(^1\) Thus, although a timely response to the "Notification To Comply With Requirements For Patent Applications Containing Nucleotide And/Or Amino Acid Sequence Disclosures" was filed on 20 November 2003, such response was not in the required format. In light of applicant's failure to file a proper response to the "Notification To Comply With Requirements For Patent Applications Containing Nucleotide And/Or Amino Acid Sequence Disclosures" mailed 15 September 2003 (and the failure to date to submit an acceptable CRF of the sequence listing), abandonment of the application was appropriate.

CONCLUSION

Applicant's petition to withdraw the holding of abandonment under 37 CFR 1.181 is **DISMISSED** without prejudice.

Any request for reconsideration of the petition must be filed within TWO (2) MONTHS of the mail date of the present application.

In the alternative, applicant might consider filing a petition to revive the unintentionally abandoned application under 37 CFR 1.137(b). Any such petition would need to be accompanied by the sequence listing materials required, including a readable CRF of the sequence listing in the proper format.

Please direct further correspondence with respect to this matter to the Mail Stop PCT, Commissioner for Patents, Office of PCT Legal Administration, P.O. Box 1450, Alexandria, Virginia 22313-1450, with the contents of the letter marked to the attention of the Office of PCT Legal Administration.

rul

Richard M. Ross PCT Petitions Attorney PCT Legal Office

Telephone: (571) 272-3296 Facsimile: (571) 273-0459

Enclosure: CRF Raw Sequence Listing Error Report processed 13 May 2004

¹ The reviewed CRF is the copy filed by applicant with the petition on 06 May 2004. Based on applicant's statements and the stamped return postcard, this CRF is treated as a copy of the CRF originally filed on 20 November 2003.